Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings
To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes. All episodes of VAP are prospectively included in a database. Information about risk factors was retr...
Gespeichert in:
Veröffentlicht in: | Intensive care medicine 2005-05, Vol.31 (5), p.649-655 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 655 |
---|---|
container_issue | 5 |
container_start_page | 649 |
container_title | Intensive care medicine |
container_volume | 31 |
creator | GARNACHO-MONTERO, José ORTIZ-LEYBA, C FERNANDEZ-HINOJOSA, Esteban ALDABO-PALLAS, Teresa CAYUELA, Aurelio MARQUEZ-VACARO, Juan A GARCIA-CURIEL, Andrés JIMENEZ-JIMENEZ, F. J |
description | To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes.
All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively.
Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens.
The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).
Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause. |
doi_str_mv | 10.1007/s00134-005-2598-0 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67783151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A151846796</galeid><sourcerecordid>A151846796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c542t-ca25e9eddea5cdaf85be04061a29d5f09e7ff695717af6992a6464172f11483d3</originalsourceid><addsrcrecordid>eNptkkFrHCEUx6U0NNu0H6CXMhTam6k6o469LSFpC4Fc2rO81edimNGtzhT67et2FwIleHgov__j6U9C3nF2zRnTnytjvB8oY5IKaUbKXpANH3pBuejHl2TD-kHQQQ3ikryu9bHRWkn-ilxyqUdphNkQu3Ux4ZJ34BYs3Q7WGVKKsfuNaYkTLLlQqDW7CAv67pBwnXOK0H3p8BA9zjFPeR8dTB0k37kppn-bEJOPaV_fkIsAU8W353pFft7d_rj5Ru8fvn6_2d5TJwexUAdCokHvEaTzEEa5QzYwxUEYLwMzqENQRmquoVUjQLV7cS0C58PY-_6KfDr1PZT8a8W62DlWh9MECfNardJ67LnkDfzwH_iY15LabFZwJfjIpWwQPUF7mNDGFPJSwO0xYYEpJwyxHW9bu3FQ2qjGXz_Dt3V8IPdsgJ8CruRaCwZ7KHGG8sdyZo9u7cmtbW7t0a1lLfP-PPm6m9E_Jc4yG_DxDEBtDkKB5GJ94pRWffsC_V-7Xawg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>216218155</pqid></control><display><type>article</type><title>Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>GARNACHO-MONTERO, José ; ORTIZ-LEYBA, C ; FERNANDEZ-HINOJOSA, Esteban ; ALDABO-PALLAS, Teresa ; CAYUELA, Aurelio ; MARQUEZ-VACARO, Juan A ; GARCIA-CURIEL, Andrés ; JIMENEZ-JIMENEZ, F. J</creator><creatorcontrib>GARNACHO-MONTERO, José ; ORTIZ-LEYBA, C ; FERNANDEZ-HINOJOSA, Esteban ; ALDABO-PALLAS, Teresa ; CAYUELA, Aurelio ; MARQUEZ-VACARO, Juan A ; GARCIA-CURIEL, Andrés ; JIMENEZ-JIMENEZ, F. J</creatorcontrib><description>To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes.
All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively.
Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens.
The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).
Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause.</description><identifier>ISSN: 0342-4642</identifier><identifier>EISSN: 1432-1238</identifier><identifier>DOI: 10.1007/s00134-005-2598-0</identifier><identifier>PMID: 15785929</identifier><identifier>CODEN: ICMED9</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>Acinetobacter baumannii ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - epidemiology ; Acinetobacter Infections - etiology ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Anti-Bacterial Agents - pharmacology ; Anti-Bacterial Agents - therapeutic use ; Antibiotics ; Antimicrobial agents ; Bacterial pneumonia ; Biological and medical sciences ; Cross infection ; Cross Infection - drug therapy ; Cross Infection - epidemiology ; Cross Infection - etiology ; Drug Resistance, Bacterial ; Emergency and intensive respiratory care ; Epidemics ; Epidemiology ; Female ; Health and social institutions ; Health aspects ; Hospitals ; Humans ; Imipenem - pharmacology ; Imipenem - therapeutic use ; Intensive care ; Intensive care medicine ; Male ; Medical prognosis ; Medical sciences ; Middle Aged ; Multivariate Analysis ; Nosocomial infections ; Organization ; Pathogens ; Patients ; Pneumonia ; Pneumonia, Bacterial - drug therapy ; Pneumonia, Bacterial - epidemiology ; Pneumonia, Bacterial - etiology ; Prognosis ; Prospective Studies ; Public health. Hygiene ; Public health. Hygiene-occupational medicine ; Regression Analysis ; Respiration, Artificial - adverse effects ; Retrospective Studies ; Risk Factors ; Spain - epidemiology ; Ventilators</subject><ispartof>Intensive care medicine, 2005-05, Vol.31 (5), p.649-655</ispartof><rights>2005 INIST-CNRS</rights><rights>COPYRIGHT 2005 Springer</rights><rights>Springer-Verlag 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c542t-ca25e9eddea5cdaf85be04061a29d5f09e7ff695717af6992a6464172f11483d3</citedby><cites>FETCH-LOGICAL-c542t-ca25e9eddea5cdaf85be04061a29d5f09e7ff695717af6992a6464172f11483d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16763017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15785929$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>GARNACHO-MONTERO, José</creatorcontrib><creatorcontrib>ORTIZ-LEYBA, C</creatorcontrib><creatorcontrib>FERNANDEZ-HINOJOSA, Esteban</creatorcontrib><creatorcontrib>ALDABO-PALLAS, Teresa</creatorcontrib><creatorcontrib>CAYUELA, Aurelio</creatorcontrib><creatorcontrib>MARQUEZ-VACARO, Juan A</creatorcontrib><creatorcontrib>GARCIA-CURIEL, Andrés</creatorcontrib><creatorcontrib>JIMENEZ-JIMENEZ, F. J</creatorcontrib><title>Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings</title><title>Intensive care medicine</title><addtitle>Intensive Care Med</addtitle><description>To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes.
All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively.
Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens.
The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).
Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause.</description><subject>Acinetobacter baumannii</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - epidemiology</subject><subject>Acinetobacter Infections - etiology</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibiotics</subject><subject>Antimicrobial agents</subject><subject>Bacterial pneumonia</subject><subject>Biological and medical sciences</subject><subject>Cross infection</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - epidemiology</subject><subject>Cross Infection - etiology</subject><subject>Drug Resistance, Bacterial</subject><subject>Emergency and intensive respiratory care</subject><subject>Epidemics</subject><subject>Epidemiology</subject><subject>Female</subject><subject>Health and social institutions</subject><subject>Health aspects</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Imipenem - pharmacology</subject><subject>Imipenem - therapeutic use</subject><subject>Intensive care</subject><subject>Intensive care medicine</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Nosocomial infections</subject><subject>Organization</subject><subject>Pathogens</subject><subject>Patients</subject><subject>Pneumonia</subject><subject>Pneumonia, Bacterial - drug therapy</subject><subject>Pneumonia, Bacterial - epidemiology</subject><subject>Pneumonia, Bacterial - etiology</subject><subject>Prognosis</subject><subject>Prospective Studies</subject><subject>Public health. Hygiene</subject><subject>Public health. Hygiene-occupational medicine</subject><subject>Regression Analysis</subject><subject>Respiration, Artificial - adverse effects</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Spain - epidemiology</subject><subject>Ventilators</subject><issn>0342-4642</issn><issn>1432-1238</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkkFrHCEUx6U0NNu0H6CXMhTam6k6o469LSFpC4Fc2rO81edimNGtzhT67et2FwIleHgov__j6U9C3nF2zRnTnytjvB8oY5IKaUbKXpANH3pBuejHl2TD-kHQQQ3ikryu9bHRWkn-ilxyqUdphNkQu3Ux4ZJ34BYs3Q7WGVKKsfuNaYkTLLlQqDW7CAv67pBwnXOK0H3p8BA9zjFPeR8dTB0k37kppn-bEJOPaV_fkIsAU8W353pFft7d_rj5Ru8fvn6_2d5TJwexUAdCokHvEaTzEEa5QzYwxUEYLwMzqENQRmquoVUjQLV7cS0C58PY-_6KfDr1PZT8a8W62DlWh9MECfNardJ67LnkDfzwH_iY15LabFZwJfjIpWwQPUF7mNDGFPJSwO0xYYEpJwyxHW9bu3FQ2qjGXz_Dt3V8IPdsgJ8CruRaCwZ7KHGG8sdyZo9u7cmtbW7t0a1lLfP-PPm6m9E_Jc4yG_DxDEBtDkKB5GJ94pRWffsC_V-7Xawg</recordid><startdate>20050501</startdate><enddate>20050501</enddate><creator>GARNACHO-MONTERO, José</creator><creator>ORTIZ-LEYBA, C</creator><creator>FERNANDEZ-HINOJOSA, Esteban</creator><creator>ALDABO-PALLAS, Teresa</creator><creator>CAYUELA, Aurelio</creator><creator>MARQUEZ-VACARO, Juan A</creator><creator>GARCIA-CURIEL, Andrés</creator><creator>JIMENEZ-JIMENEZ, F. J</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20050501</creationdate><title>Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings</title><author>GARNACHO-MONTERO, José ; ORTIZ-LEYBA, C ; FERNANDEZ-HINOJOSA, Esteban ; ALDABO-PALLAS, Teresa ; CAYUELA, Aurelio ; MARQUEZ-VACARO, Juan A ; GARCIA-CURIEL, Andrés ; JIMENEZ-JIMENEZ, F. J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c542t-ca25e9eddea5cdaf85be04061a29d5f09e7ff695717af6992a6464172f11483d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Acinetobacter baumannii</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - epidemiology</topic><topic>Acinetobacter Infections - etiology</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibiotics</topic><topic>Antimicrobial agents</topic><topic>Bacterial pneumonia</topic><topic>Biological and medical sciences</topic><topic>Cross infection</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - epidemiology</topic><topic>Cross Infection - etiology</topic><topic>Drug Resistance, Bacterial</topic><topic>Emergency and intensive respiratory care</topic><topic>Epidemics</topic><topic>Epidemiology</topic><topic>Female</topic><topic>Health and social institutions</topic><topic>Health aspects</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Imipenem - pharmacology</topic><topic>Imipenem - therapeutic use</topic><topic>Intensive care</topic><topic>Intensive care medicine</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Nosocomial infections</topic><topic>Organization</topic><topic>Pathogens</topic><topic>Patients</topic><topic>Pneumonia</topic><topic>Pneumonia, Bacterial - drug therapy</topic><topic>Pneumonia, Bacterial - epidemiology</topic><topic>Pneumonia, Bacterial - etiology</topic><topic>Prognosis</topic><topic>Prospective Studies</topic><topic>Public health. Hygiene</topic><topic>Public health. Hygiene-occupational medicine</topic><topic>Regression Analysis</topic><topic>Respiration, Artificial - adverse effects</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Spain - epidemiology</topic><topic>Ventilators</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>GARNACHO-MONTERO, José</creatorcontrib><creatorcontrib>ORTIZ-LEYBA, C</creatorcontrib><creatorcontrib>FERNANDEZ-HINOJOSA, Esteban</creatorcontrib><creatorcontrib>ALDABO-PALLAS, Teresa</creatorcontrib><creatorcontrib>CAYUELA, Aurelio</creatorcontrib><creatorcontrib>MARQUEZ-VACARO, Juan A</creatorcontrib><creatorcontrib>GARCIA-CURIEL, Andrés</creatorcontrib><creatorcontrib>JIMENEZ-JIMENEZ, F. J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Intensive care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>GARNACHO-MONTERO, José</au><au>ORTIZ-LEYBA, C</au><au>FERNANDEZ-HINOJOSA, Esteban</au><au>ALDABO-PALLAS, Teresa</au><au>CAYUELA, Aurelio</au><au>MARQUEZ-VACARO, Juan A</au><au>GARCIA-CURIEL, Andrés</au><au>JIMENEZ-JIMENEZ, F. J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings</atitle><jtitle>Intensive care medicine</jtitle><addtitle>Intensive Care Med</addtitle><date>2005-05-01</date><risdate>2005</risdate><volume>31</volume><issue>5</issue><spage>649</spage><epage>655</epage><pages>649-655</pages><issn>0342-4642</issn><eissn>1432-1238</eissn><coden>ICMED9</coden><abstract>To investigate prognostic factors and predictors of Acinetobacter baumannii isolation in ventilator-associated pneumonia (VAP). We specifically analyzed these issues for imipenem-resistant episodes.
All episodes of VAP are prospectively included in a database. Information about risk factors was retrieved retrospectively.
Eighty-one patients exhibiting microbiologically documented VAP: 41 by A. baumannii (26 by imipenem-resistant) and 40 by other pathogens.
The following variables were noted: underlying diseases, severity of illness, duration of mechanical ventilation and of hospitalization before VAP, prior episode of sepsis, previous antibiotic, corticosteroid use, type of nutrition, renal replacement therapy, reintubation, transportation out of the ICU, micro-organisms involved in VAP, concomitant bacteremia, clinical presentation, Sequential Organ Failure Assessment (SOFA) scale on the day of diagnosis, and adequacy of empirical antibiotic therapy. Prior antibiotic use was found to be associated with development of VAP by A. baumannii (OR 14). Prior imipenem exposure was associated with the isolation of imipenem-resistant strains (OR 4). SOFA score on the day of diagnosis was the only predictor of in-hospital mortality (OR 1.22); adequacy of empirical antibiotic therapy was a protective factor (OR 0.067).
Our results confirm that prior exposure to antimicrobials is an independent predictor for the development of A. baumannii VAP, the prognosis of which is similar to that of infections caused by other pathogens. This study highlights the importance of initial antibiotic choice in VAP or whatever cause.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>15785929</pmid><doi>10.1007/s00134-005-2598-0</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0342-4642 |
ispartof | Intensive care medicine, 2005-05, Vol.31 (5), p.649-655 |
issn | 0342-4642 1432-1238 |
language | eng |
recordid | cdi_proquest_miscellaneous_67783151 |
source | MEDLINE; Springer Nature - Complete Springer Journals |
subjects | Acinetobacter baumannii Acinetobacter Infections - drug therapy Acinetobacter Infections - epidemiology Acinetobacter Infections - etiology Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Antibiotics Antimicrobial agents Bacterial pneumonia Biological and medical sciences Cross infection Cross Infection - drug therapy Cross Infection - epidemiology Cross Infection - etiology Drug Resistance, Bacterial Emergency and intensive respiratory care Epidemics Epidemiology Female Health and social institutions Health aspects Hospitals Humans Imipenem - pharmacology Imipenem - therapeutic use Intensive care Intensive care medicine Male Medical prognosis Medical sciences Middle Aged Multivariate Analysis Nosocomial infections Organization Pathogens Patients Pneumonia Pneumonia, Bacterial - drug therapy Pneumonia, Bacterial - epidemiology Pneumonia, Bacterial - etiology Prognosis Prospective Studies Public health. Hygiene Public health. Hygiene-occupational medicine Regression Analysis Respiration, Artificial - adverse effects Retrospective Studies Risk Factors Spain - epidemiology Ventilators |
title | Acinetobacter baumannii ventilator-associated pneumonia : epidemiological and clinical findings |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T01%3A34%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Acinetobacter%20baumannii%20ventilator-associated%20pneumonia%20:%20epidemiological%20and%20clinical%20findings&rft.jtitle=Intensive%20care%20medicine&rft.au=GARNACHO-MONTERO,%20Jos%C3%A9&rft.date=2005-05-01&rft.volume=31&rft.issue=5&rft.spage=649&rft.epage=655&rft.pages=649-655&rft.issn=0342-4642&rft.eissn=1432-1238&rft.coden=ICMED9&rft_id=info:doi/10.1007/s00134-005-2598-0&rft_dat=%3Cgale_proqu%3EA151846796%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=216218155&rft_id=info:pmid/15785929&rft_galeid=A151846796&rfr_iscdi=true |